Barclays
TCRX icon

Barclays’s TScan Therapeutics TCRX Stock Holding History

Barclays’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3K Sell
17,080
-6,116
-26% -$6.54K ﹤0.01% 4604
2025
Q4 		$23.2K Buy
23,196
+4,119
+22% +$5.96K ﹤0.01% 4857
2025
Q3 		$34.7K Sell
19,077
-2,101
-10% -$3.72K ﹤0.01% 4853
2025
Q2 		$30.7K Sell
21,178
-40,672
-66% -$58.8K ﹤0.01% 4785
2025
Q1 		$85.4K Sell
61,850
-5,658
-8% -$12.2K ﹤0.01% 4462
2024
Q4 		$205K Buy
67,508
+9,441
+16% +$42.8K ﹤0.01% 4293
2024
Q3 		$289K Buy
58,067
+44,903
+341% +$271K ﹤0.01% 4108
2024
Q2 		$77K Buy
+13,164
New +$104K ﹤0.01% 4032
2022
Q2 		– Sell
-158,944
Closed -$445K – 5264
2022
Q1 		$445K Buy
+158,944
New +$687K ﹤0.01% 2980

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Barclays's TCRX Position: Q1 2026 in Review

Barclays reduced its TScan Therapeutics (TCRX) stake by 26% in Q1 2026, selling an estimated $6.54K and leaving 17,080 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4604.

Barclays first reported a position in TCRX in Q1 2022 and has held it in 9 quarters since. The position peaked at $445K in Q1 2022. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Barclays held 17,080 shares of TScan Therapeutics worth $17.3K as of Q1 2026.
  • Barclays sold 6,116 TScan Therapeutics shares in Q1 2026, an estimated $6.54K.
  • TScan Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4604 holding.
  • Barclays first reported a position in TScan Therapeutics in Q1 2022 and has held it in 9 quarters since.
  • Barclays's TScan Therapeutics position peaked at $445K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.